
Retinopathy: Golgi and Breye join forces
The two companies announced their collaboration, which aims to find treatment options for both early-stage diabetic retinopathy (DR) and dry-AMD...

Resistance blocker of immune checkpoint inhibitors gets patented
DT-9081, Domain Therapeutics’ selective EP4 receptor antagonist, preclinically synergised with PD1-checkpoint blockers and shrinked tumours by...

NK cell therapy company NK:IO raises seed money
London-based UK New Cancer Therapeutics award winner (£1.6m) NK:IO Ltd has raised £1.2M bringing total equity financing to £3.2m. This,...

Astraveus SAS bags €16.5m in seed financing
The oversubscribed seed round of Astraveus SAS was led by AdBio partners, co-syndicated with M Ventures, Johnson & Johnson Innovation –...

Santhera licences vamorolone rights to Catalyst Pharmaceuticals
Pratteln-based Santhera Pharmaceuticals Holding got a US$90m upfront payment from Catalyst Pharmaceuticals Inc for the Northern America vamorolone...

Neogap fully takes over TCER Oncology shares
Neogap Therapeutics A/B was joined by new shareholders Prof. Rolf Kiessling and his team member Stina Wickström who took over the remaining...

EU Regulation of Genome Editing in Plants – not yet a law
The EU proposal has a clear message: the requirements for simple genome-edited plants shall be significantly relaxed. There will no longer be the...